Disruption of GCN2 Pathway Aggravates Vascular and Parenchymal Remodeling during Pulmonary Fibrosis.

Animals Humans Male Rats Bleomycin Endothelial Cells / pathology Hypertension, Pulmonary / pathology Lung / pathology Protein Serine-Threonine Kinases / metabolism Pulmonary Fibrosis / pathology Rats, Sprague-Dawley
lung diseases right ventricular dysfunction vascular disease

Journal

American journal of respiratory cell and molecular biology
ISSN: 1535-4989
Titre abrégé: Am J Respir Cell Mol Biol
Pays: United States
ID NLM: 8917225

Informations de publication

Date de publication:
03 2023
Historique:
pubmed: 9 12 2022
medline: 4 3 2023
entrez: 8 12 2022
Statut: ppublish

Résumé

Pulmonary fibrosis (PF) and pulmonary hypertension (PH) are chronic diseases of the pulmonary parenchyma and circulation, respectively, which may coexist, but underlying mechanisms remain elusive. Mutations in the GCN2 (general control nonderepressible 2) gene (

Identifiants

DOI: 10.1165/rcmb.2021-0541OC PMID: 36476191
pubmed: 36476191
doi: 10.1165/rcmb.2021-0541OC
doi:

Substances chimiques

Bleomycin 11056-06-7
EIF2AK4 protein, human EC 2.7.11.1
Protein Serine-Threonine Kinases EC 2.7.11.1
Eif2ak4 protein, rat EC 2.7.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

326-338

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL157100
Pays : United States

Commentaires et corrections

Type : CommentIn

Auteurs

Diana Santos-Ribeiro (D)

Pneumology, ENT and Dermatology.
ORCID: 0000-0003-2528-142X

Marylène Lecocq (M)

Pneumology, ENT and Dermatology.

Michèle de Beukelaer (M)

Imaging Platform (2IP).

Stijn Verleden (S)

Laboratory of Respiratory Diseases & Thoracic Surgery, Department of Chronic Diseases and Metabolism, and.

Caroline Bouzin (C)

Imaging Platform (2IP).

Jérôme Ambroise (J)

Applied Molecular Technologies Center.

Peter Dorfmuller (P)

Department of Pathology, University of Giessen and Marburg Lung Center, Justus-Liebig University Giessen, German Center for Lung Research, Giessen, Germany.

Yousef Yakoub (Y)

Louvain Center for Toxicology and Applied Pharmacology, and.

François Huaux (F)

Louvain Center for Toxicology and Applied Pharmacology, and.

Rozenn Quarck (R)

Clinical Department of Respiratory Diseases, University Hospitals - University of Leuven, Leuven, Belgium.
ORCID: 0000-0002-8293-6261

Harry Karmouty-Quintana (H)

Department of Biochemistry and Molecular Biology and.
Division of Critical Care and.
Division of Pulmonary and Sleep Medicine, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, Texas.
ORCID: 0000-0003-4753-9823

Maria-Rosa Ghigna (MR)

Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
Département de Pathologie and.
INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.

Juliette Bignard (J)

UMR_S 1166-ICAN, INSERM, Sorbonne Université, Paris, France.

Sophie Nadaud (S)

UMR_S 1166-ICAN, INSERM, Sorbonne Université, Paris, France.

Florent Soubrier (F)

UMR_S 1166-ICAN, INSERM, Sorbonne Université, Paris, France.

Sandrine Horman (S)

Cardiovascular Research Unit, Institute of Experimental and Clinical Research, Catholic University of Louvain, Brussels, Belgium.

Frederic Perros (F)

Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.
Assistance Publique-Hôpitaux de Paris, Centre de Référence de l'Hypertension Pulmonaire, Service de Pneumologie et Soins Intensifs Respiratoires, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
Laboratoire CarMeN, UMR INSERM U1060/INRA U1397, Université Claude Bernard Lyon1, Pierre-Bénite and Bron, France; and.

Laurent Godinas (L)

Clinical Department of Respiratory Diseases, University Hospitals - University of Leuven, Leuven, Belgium.

Charles Pilette (C)

Pneumology, ENT and Dermatology.
Département de Pneumologie, Cliniques Universitaires St-Luc, Brussels, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Disruption of GCN2 Pathway Aggravates Vascular...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Disruption of GCN2 Pathway Aggravates Vascular...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Rats › Disruption of GCN2 Pathway Aggravates Vascular...
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Glycopeptides › Bléomycine › Disruption of GCN2 Pathway Aggravates Vascular...
questionsmedicales.fr › Cellules › Cellules épithéliales › Cellules endothéliales › Disruption of GCN2 Pathway Aggravates Vascular...
questionsmedicales.fr › Maladies cardiovasculaires › Maladies vasculaires › Hypertension artérielle › Hypertension pulmonaire › Disruption of GCN2 Pathway Aggravates Vascular...
questionsmedicales.fr › Appareil respiratoire › Poumon › Disruption of GCN2 Pathway Aggravates Vascular...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protein-Serine-Threonine Kinases › Disruption of GCN2 Pathway Aggravates Vascular...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Fibrose › Fibrose pulmonaire › Disruption of GCN2 Pathway Aggravates Vascular...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Rats › Rat Sprague-Dawley › Disruption of GCN2 Pathway Aggravates Vascular...